SA国际传媒

The Greater Boston area鈥檚 startup scene has long been seen as synonymous, even exclusive, to its biotechnology lineup.

Subscribe to the SA国际传媒 Daily

But let鈥檚 say we strip away the tech-focused neighbors of Boston, like Cambridge for example. You鈥檒l see that Boston alone might be viewed as more than a healthcare-focused town.

Looking at the last 12 months within Boston, out of the 10 biggest funding rounds, only one went to a traditional biotech company: Karuna Therapeutics, a developer of drugs for the treatment of schizophrenia. It raised a in March, led by ARCH Venture Partners.

Extra Servings

, Boston-based startups that work with food鈥攆rom catering to developing ingredients for plant-based protein鈥攈ave raised significant funding.

For example, , the CEO and founder of catering service , started a food company in an area where food is not the primary industry has worked out well. The company, which uses software to connect caterers to companies, raised nine-figure rounds twice in the past year.

The city’s ability to change has been key in her success. When she graduated from Massachusetts Institute of Technology in 1977, for example, Boston was pivoting from the hardware capital of the world, to the software capital of the world.

鈥淏ut then that disappeared too, and a lot of it went to the West Coast…but it never died,鈥� she said. 鈥淚t鈥檚 just been eclipsed by things like pharma and biotech.鈥� She said a few high-tech companies beyond biotech have found a home in Boston as a result of previous software roots.

As Mary Ann Azevedo reported, the company has more than doubled in revenue and bookings every single year for the last seven years.

One of those companies includes , a restaurant management platform launched in 2013 that is now valued at around $2.7 billion. It raised the biggest round within Boston during the past 12 months. In March, Toast raised a $250 million Series E, at which time the company its revenue grew 148 percent in 2018.

The 1,500-person company told SA国际传媒 News that it plans to invest over $1 billion in research and development over the next five years. Touching on Mallett’s earlier comments, Toast says part of that money will go to building software and hardware to cater to the restaurant industry.

Jumping away from late-stage unicorns, but staying in the food realm, early-stage company also made the list with its $90 million Series A, for meatless protein. In a world seemingly-ruled by Impossible Foods and Beyond Meat, Motif similarly looks to use fermentation to develop proteins and nutrients. The company has bits of biotech embedded in its DNA, as Motif Ingredients spun out of Boston-based biotech unicorn .

In a statement, Motif said it will use biotechnology rather than animal agriculture to engineer dozens of proteins, derived from dairy, egg and meat.

As Boston pivots beyond biotech, Silicon Valley-based investors have taken notice, and a liking to its new offerings. In our list, a slew of Bay Area investors鈥�, , , , and others鈥攁re found on the term sheets of Boston鈥檚 largest rounds.

Illustration: .